Molecular, Genetic, and Genomic Assessments of MTOR Inhibition in Metastatic Hormone-Refractory Prostate Cancer Tissue From Patients Treated With RAD001.
Phase of Trial: Phase IV
Latest Information Update: 19 Jun 2013
At a glance
- Drugs Everolimus (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 14 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jun 2011 Planned end date changed from 1 Dec 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.